Open access · OA
via OpenAlex
Disease Modification: Comparing Diverse Approaches to Alpha-Synuclein Targeting Therapies in Parkinson’s Disease
International journal of high school research · 2025
Abstract
Parkinson's disease (PD) is a prevalent neurodegenerative disorder that mainly affects people over the age of 60.The characteristic movement-related complications, including tremors, akinesia, as well as nonmotor symptoms such as mood disorders, arise when neurodegeneration within the substantia nigra causes a lack of dopamine, creating dysfunction in many systems.A key pathological hallmark of PD is the accumulation of misfolded α-synuclein (ASYN), forming toxic aggregates responsible for disease progression.Even with billions spent on healthcare, millions of lives affected, and multiple symptomatic treatments available, there are currently no disease-modifying therapies to slow PD progression.This review compares ten current alpha-synuclein-targeting disease-modifying therapies in clinical trials explored in the Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update.Because each clinical trial used different biomarkers to prove the slowing neurodegeneration, the drugs were compared on whether they showed a decrease in ASYN aggregates and viability on a cellular level.These therapeutic approaches aimed to reduce pathologic ASYN levels through various mechanisms ranging from antibodies, neurotransmitter regulators, and small molecule therapies.Among them, the small molecule therapies, specifically UCB0599 and Anle-138b, seemed to be the most promising given the greatest blood-brain barrier penetration and decreased pathological alpha-synuclein levels.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.36838/v7i4.11
- Canonical
- link ↗
- Fetched
- 2026-10-21 MST
Cite this
APA
Kim, J. (2025). Disease Modification: Comparing Diverse Approaches to Alpha-Synuclein Targeting Therapies in Parkinson’s Disease. <em>International journal of high school research</em>. https://doi.org/10.36838/v7i4.11
Vancouver
Kim J. Disease Modification: Comparing Diverse Approaches to Alpha-Synuclein Targeting Therapies in Parkinson’s Disease. International journal of high school research. 2025. doi:10.36838/v7i4.11.
BibTeX
@article{john2025Diseas,
title = {Disease Modification: Comparing Diverse Approaches to Alpha-Synuclein Targeting Therapies in Parkinson’s Disease},
author = {John Kim},
journal = {International journal of high school research},
year = {2025},
doi = {10.36838/v7i4.11},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Journal of Neuroscience 2003
Open access · OA
Cocaine Abusers Have an Overexpression of α-Synuclein in Dopamine Neurons
Progress in Lipid Research 2010
Citation only
Alpha-synuclein, lipids and Parkinson’s disease
Pharmacological Reviews 2022
Open access · CC-BY
Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease
Neurobiology of Disease 2022
Open access · CC-BY
Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders
Scientific Reports 2017
Open access · CC-BY
Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson’s disease
Current Neuropharmacology 2018
Open access · OA